Quantifying Genetic Stability And Quality Control Of Multiple Integrations Of Orthogonal Transposases

Looking to uncover the intricacies of transposase-mediated genome engineering, genetic quality control (QC), and the stability of orthogonal transposons in cell line generation? In this session, the following experts will showcase how they leverage Leap-In Transposase® technology to genetically engineer Chinese hamster ovary (CHO) cells iteratively, enabling precise control over their expression profiles:

• Maya Wright Clark, PhD, Sales and Account Manager, Cergentis
• Mário Pereira, Director of Technologies and Business Development, ATUM

This groundbreaking approach offers a reliable method for introducing genes encoding biotherapeutic proteins into mammalian genomes, bypassing challenges associated with random integration or viral-based delivery systems. Through the strategic application of three distinct and orthogonal Leap-In Transposase® enzymes, the teams were able to successfully create a diverse panel of CHO cell lines. These lines have been tailored to modulate metabolic pathways for enhanced selection, integrate biotherapeutic proteins, and modify glycosylation profiles, resulting in stable, high-expression cell lines with desired product quality attributes.

To ensure accurate integration and demonstrate orthogonality, genetic QC has been conducted using Targeted Locus Amplification (TLA) coupled with next-generation sequencing (NGS). This comprehensive analysis facilitates the identification and genetic characterization of all transposon integration sites. Furthermore, the comparison of TLA data across different time points allows for the assessment of genetic stability and integrity.

Delve into transposase-mediated genome engineering, genetic quality control, and the maintenance of genetic stability in cell line generation with Leap-In Transposase® technology by watching the full webinar below.